arXiv:2101.04617v1 [cs.CL] 12 Jan 2021

AI- and HPC-enabled Lead Generation for SARS-CoV-2:
Models and Processes to Extract Druglike Molecules Contained in
Natural Language Text
Zhi Hong1 , J. Gregory Pauloski1 , Logan Ward2 , Kyle Chard1,2 , Ben Blaiszik3,2 , and Ian
Foster1,2
1

2

Department of Computer Science, University of Chicago
Data Science and Learning Division, Argonne National Laboratory
3
Globus, University of Chicago, Chicago, IL, USA

January 13, 2021

Abstract
Researchers worldwide are seeking to repurpose existing drugs or discover new drugs to counter
the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A promising source of candidates for such studies is molecules that have been reported in the scientific
literature to be drug-like in the context of coronavirus research. We report here on a project
that leverages both human and artificial intelligence to detect references to drug-like molecules
in free text. We engage non-expert humans to create a corpus of labeled text, use this labeled
corpus to train a named entity recognition model, and employ the trained model to extract
10 912 drug-like molecules from the COVID-19 Open Research Dataset Challenge (CORD-19)
corpus of 198 875 papers. Performance analyses show that our automated extraction model can
achieve performance on par with that of non-expert humans.

1

Introduction

The Coronavirus Disease (COVID-19) pandemic, caused by transmissible infection of the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in tens of millions of
diagnosed cases and over 1 450 000 deaths worldwide [1]; straining healthcare systems, and
disrupting key aspects of society and the wider economy. It is thus important to identify
effective treatments rapidly via discovery of new drugs and repurposing of existing drugs. Here,
we leverage advances in natural language processing to enable automatic identification of drug
candidates being studied in the scientific literature.
The magnitude of the pandemic has resulted in an enormous number of academic publications
related to COVID-19 research since early 2020. Many of these articles are collated in the COVID19 Open Research Dataset Challenge (CORD-19) collection [2, 3]. With 198 875 articles at the
time of writing, that collection is far too large for humans to read. Thus, tools are needed to
automate the process of extracting relevant data, such as drug names, testing protocols, and
protein targets. Such tools can save domain experts significant time and effort.
Towards this goal, we describe here how we have tackled two important problems: creating
labelled training data via judicious use of scarce human expertise, and applying a named entity

1

recognition (NER) model to automatically identify drug-like molecules in text. In the absence
of rich labeled data for the growing COVID literature, we employ an iterative model-in-the-loop
collection process inspired by our previous work [4, 5]. We first assemble a small bootstrap
set of human-verified examples to train a model for identifying similar examples. We then
iteratively apply the model, use human reviewers to verify the predictions for which the model
is least confident, and retrain the model until the improvement in performance is less than a
threshold. (The human reviewers were administrative staff without scientific backgrounds, with
time available for this task due to the pandemic.)
Having collected adequate training data via this model-guided human annotation process,
we then use the resulting labeled data to re-train a NER model originally developed to identify
polymer names in materials science publications [6] and apply this trained model to CORD-19.
We show that the labeled data produced by our approach are of sufficiently high quality than
when used to train NER models, which achieves a best F-1 score of 80.5%‚Äîroughly equivalent
to that achieved by non-expert humans.
The labeled data, model, and model results are all available online, as described in Section 7.

2

Problem Definition

We aim to develop and apply new computational methods to mine the scientific literature to
identify small molecules that have been investigated or found useful as antiviral therapeutics.
For example, processing the following sentence should allow us to determine that the drug sofosbuvir has been found effective against the Zika virus: ‚ÄúSofosbuvir, an FDA-approved nucleotide
polymerase inhibitor, can efficiently inhibit replication and infection of several ZIKV strains,
including African and American isolates.‚Äù [7].
This problem of identifying drug-like molecules in text can be divided into two linked problems: 1) identifying references to small therapeutic molecules (‚Äúdrugs‚Äù) and 2) determining
what the text says about those molecules. In this work, we consider potential solutions to the
first problem.
A simple way to identify entities in text that belong to a specialized class (e.g., drug-like
molecules) is to refer to a curated list of valid names, if such is available. In the case of drugs,
we might think to use DrugBank [8] or the FDA Drug Database [9], both of which in fact list
sofosbuvir. However, such databases are not in themselves an adequate solution to our problem,
for at least two reasons. First, they are rarely complete. The tens of thousands of entity names
in DrugBank and the FDA Drug Database together are just a tiny fraction of the billions of
molecules that could potentially be used as drugs. Second, such databases may be overly general:
DrugBank, for example, includes the terms ‚Äúrabbit‚Äù and ‚Äúcalcium,‚Äù neither of which have value
as antiviral therapeutics. In general, the use of any such list to identify entities will lead to
both false negatives and false positives. We need instead to employ the approach that a human
reader might follow in this situation, namely to scan text for words that appear in contexts in
which a drug name is likely to appear. In the following, we explain how we use natural language
processing (NLP) techniques for this purpose.

3

Automated Drug Entity Extraction from Literature

Finding strings in text that refer to drug-like molecules is an example of named-entity recognition
(NER) [10], an important NLP task. Both grammatical and statistical (e.g., neural networkbased) methods have been applied to NER; the former can be more accurate, but require much
effort from trained linguists to develop. Statistical methods use supervised training on labeled
examples to learn the contexts in which entities of interest (e.g., drug-like molecules) are likely
to occur, and then classify previously unseen words as such entities if they appear in similar
contexts. For instance, a training set may contain the sentence ‚ÄúRibavirin was administered
once daily by the i.p. route‚Äù [11], with ribavirin labelled as Drug. With sufficient training
data, the model may learn to assign the label Drug to arbidol in the sentence ‚ÄúArbidol was

2

administered once daily per os using a stomach probe‚Äù [11]. This learning approach can lead
to general models capable of finding previously unseen candidate molecules in natural language
text.
The development of effective statistical NER models is complicated by the many contexts in
which names can occur. For example, while the contexts just given for ribavirin and arbidol are
similar, both are quite different from that quoted for sofosbuvir earlier. Furthermore, authors
may use different wordings and sentence structures: e.g., ‚Äúgiven by i.p. injection once daily‚Äù
rather than ‚Äúadministered once daily by the i.p. route.‚Äù Thus, statistical NER methods need to
do more than learn template word sequences: they need to learn more abstract representations
of the context(s) in which words appear. Modern NLP and NER systems do just that [12].

3.1

SpaCy and Keras-LSTM Models

We consider two NER models in this paper, SpaCy and a Keras long-short term memory (LSTM)
model. Both models are publicly available on DLHub [13] and GitHub, as described in Section 7.
SpaCy is an open source NLP library that provides a pre-trained entity recognizer that
can recognize 18 types of entities, including PERSON, ORGANIZATION, LOCATION, and
PRODUCT. Its model calculates a probability distribution of a word over the entity types,
and outputs the type with the highest probability as the predicted type for that word. When
pre-trained on the OntoNotes 5 dataset of over 1.5 million labeled words [14], the SpaCy entity
recognizer can identify supported entities with 85.85% accuracy. However, it does not include
drug names as a supported entity class, and thus we would need to retrain the SpaCy model on
a drug-specific training corpus. Unfortunately, there is no publicly available corpus of labeled
text for drug-like molecules in context. Thus, we need to use other methods to retrain this
model (or other NER models), as we describe in Section 4.
While SpaCy is easy to use, it lacks flexibility: its end-to-end encapsulation does not expose
many tunable parameters. Thus we also explore the use of a Keras-LSTM model that we
developed in previous work for identification of polymers in materials science literature [6]. This
model is based on the Bidirectional LSTM network with a conditional random field (CRF) layer
added on top. It takes training data labeled according to the ‚ÄúIOB‚Äù schema. The first word in
an entity is given the label ‚ÄúB‚Äù (Beginning), the following words in the same entity are labeled
‚ÄúI‚Äù (Inside), and non-entity words are labeled ‚ÄúO‚Äù (outside). During prediction, the Bi-LSTM
network tries to assign one of ‚ÄúIOB‚Äù to each word in the input sentence, but it has no awareness
of the validity of the label sequence. The CRF layer is used on top of Bi-LSTM to lower the
probability of invalid label sequences (e.g., ‚ÄúOIO‚Äù).
We compare the performance of SpaCy and Keras-LSTM models under various conditions
in Section 4.

3.2

Model-in-the-Loop Annotation Workflow

We address the lack of labeled training data by using Algorithm 1 (and see Figure 1) to assemble
a set of human- and machine-labeled data from CORD-19 [3]. In describing this process, we refer
to paragraphs labeled automatically via a heuristic or model as silver and to silver paragraphs
for which labels have been corrected by human reviewers as gold. We use the Prodigy machine
learning annotation tool to manage the review process: reviewers are presented with a silver
paragraph, with putative drug entities highlighted; they click on false negative and false positive
words to add or remove the highlights and thus produce a gold paragraph. Prodigy saves the
corrected labels in standard NER training data format.
Our algorithm involves three main phases, as follows. In the first bootstrap phase, we
assemble an initial test set of gold paragraphs for use in subsequent data acquisition. We create
a first set of silver paragraphs by using a simple heuristic: we select N0 paragraphs from CORD19 that contain one or more words in DrugBank with an Anatomical Therapeutic Chemical
Classification System (ATC) code, label those words as drugs, and ask human reviewers to
correct both false positives and false negatives in our silver paragraphs, creating gold paragraphs.

3

In the subsequent build test set phase, we repeatedly use all gold paragraphs obtained so far
to train an NER model; use that model to identify and label additional silver paragraphs, and
engage human reviewers to correct false positives and false negatives, creating additional gold
paragraphs. We repeat this process until we have Nt initial gold paragraphs.
In the third build labeled set phase, we repeatedly use an NER model trained on all humanvalidated labels obtained to date, with the Nt gold paragraphs from the bootstrap phase used as
a test set, to identify and label promising paragraphs in CORD-19 for additional human review.
To maximize the utility of this human effort, we present the reviewers only with paragraphs that
contain one or more uncertain words, i.e., words that the NER model identifies as drug/nondrug with a confidence in the range [min, max]). We continue this process of model retraining,
paragraph selection and labeling, and human review until the F-1 score improves by less than .
The behavior of this algorithm is influenced by six parameters: N0 , N , Nt , , min, and max.
N0 and N are the number of paragraphs that are assigned to human reviewers in the first and
subsequent steps, respectively. Nt is the number of examples in the test set.  is a threshold
that determines when to stop collecting data. The min and max determine the confidence range
from which words are selected for human review. In the experimental studies described below,
we used N0 =278, N =120, Nt =500, =0, min=0.45, and max=0.55.
The NER model used in the model-in-the-loop annotation workflow to score words might
also be viewed as a parameter. In the work reported here, we use SpaCy exclusively for that
purpose, as it integrates natively with the Prodigy annotation tool and trains more rapidly.
However, as we show below, the Keras-LSTM model is ultimately somewhat more accurate
when trained on all of the labeled data generated, and thus is preferred when processing the
entire CORD-19 dataset: see Section 5.1 and Section 6.

Algorithm 1: Model-in-the-loop Annotation Workflow
1

2
3
4

5
6
7
8
9
10
11
12

13
14
15
16
17
18

C := randomized paragraphs(CORD) ;
// Prepare CORD-19 paragraphs
/* A) Bootstrap: Identify first silver paragraphs
*/
D := {s : s ‚àà DrugBank & ATC(s)} ;
// Extract names from DrugBank
P0 := {p : p = next(C) & p ‚à© D =
6 ‚àÖ} & |P0 | = N0 ;
// Assemble first silver set
B = verify(P0 ) ;
// Verify labels; initialize bootstrap set
/* B) Build test set: Expand on bootstrap set from (A)
*/
while |B| < Nt do
M := NER(train = 0.6B, test = 0.4B) ;
// Train: 60-40 train-test split
P := {p : p = next(C) & ‚àÉw ‚àà p : M(w) ‚àà [min, max])} & |P| = N ; // Next silver
V := verify(P) ;
// Engage crowd to verify labels
B := B ‚à™ V ;
// Add corrected paragraphs to bootstrap set
end
T = B[: Nt ] ;
// Initialize test set to first Nt examples
G = B[Nt :] ;
// Initialize gold set to any remaining examples
/* C) Build labeled set: Use test set from (B) to evolve model
*/
while F-1 score improvement >  do
M := NER(train = G, test = T ) ;
// Train on G, test on T
P := {p : p = next(C) & ‚àÉw ‚àà p : M(w) ‚àà [min, max])} & |P| = N ; // Next silver
V := verify(P) ;
// Engage crowd to verify labels
G := G ‚à™ V ;
// Add corrected paragraphs to gold set
end

This semi-automated method saves time and effort for human reviewers because they are
only asked to verify labels that have already been identified by our model to be uncertain,
and thus worth processing. Furthermore, as we show below, we find that we do not need to
engage biomedical professionals to label drugs in text: untrained people, armed with contextual
information (and online search engines), can spot drug names in text with accuracy comparable
to that of experts.
We provide further details on the three phases of the algorithm in the following, with numbers

4

A) Bootstrap

Inputs

B) Build test set

Select: DrugBank words
Labels: DrugBank word=Drug
Iterations: 1
Review: N0=278
Output: Labeled bootstrap set

DNN model

DrugBank

Label with
DrugBank
words

Select: Uncertain words
Labels: Model=Drug
Iterations: 5 x N=120
Review: 5 x 120 = 600
Output: Test set, gold set

Human
review of
labels

Key

Bootstrap
set
N0=278

Select: Uncertain words
Review: 960
Labels: Model=Drug
Output: Labeled set, model
Iterations: Until F-1 score improvement < ùú∫=0, i.e., 8 x (N=120) =960

~1000
validated
paragraphs
Labeled text

Model weights

Final trained
weights

Accumulate
gold
paragraphs

DNN model
weights
Model training

Accumulate
gold
paragraphs

Extra gold
(100)

C) Build labeled set

Outputs

Labeled and validated

Human
review of
labels

next
CORD-19

Labeled, not validated

Test set
Nt=500

Human
review of
labels

Figure 1: Overview of the training data collection workflow, showing the three phases
described in the text and with the parameter values used in the study reported here. Each
phase pulls paragraphs from the CORD-19 dataset (blue dashed line) according to the Select
criterion listed in its shaded box. Phases B and C repeatedly update the weights for the
NER model (green arrows) that they use to identify and label uncertain paragraphs; human
review (yellow and gold arrows) corrects those silver paragraphs to yield gold paragraphs.
Total human review work is ‚àº278+600+960=1838 paragraphs.
in the list referring to line numbers in Algorithm 1.
A) Bootstrap
1 We start with the 2020-03-20 release version of the CORD-19 corpus, which contains
44 220 papers [3]. We create C, a random permutation of its paragraphs from which we
will repeatedly fetch paragraphs via next(C).
2 We bootstrap the labeling process by identifying as D the 2675 items in the DrugBank
ontology with a Anatomical Therapeutic Chemical Classification System (ATC) code attached (eliminating many, but not all, druglike molecule entities).
3 We create an initial set of silver paragraphs, P0 , by selecting N0 paragraphs from C that
include a word from D.
4 We engage human reviewers to remove false positives and label false negatives in P0 ,
yielding an initial set of gold paragraphs, B.
B) Build test set
5 We expand the test set that we will use to evaluate the model created in the next phase,
until we have Nt validated examples.
6 We train the NER model on 60% of the data collected to date and evaluate it on the
remaining 40%, to create a new trained model, M, with improved knowledge of the types
of entities that we seek.
7 We use the probabilities over entities returned by the model to select, as our N new silver
paragraphs, P, paragraphs that contain at least one uncertain word (see above).
8 We engage human reviewers to convert these new silver paragraphs, P, to gold, V.
9 We add the new gold paragraphs, V, to the bootstrap set B.
11‚Äì12 Having assembled at least Nt validated examples, we select the first Nt as the test set, T ,
and use any remaining examples to initialize the new gold set, G.

5

C) Build labeled set
13 We assemble a training set G, using the test set T assembled in the previous phases for
testing. This process continues until the F-1 score stops improving (see Section 4).
14‚Äì17 Same as Steps 6‚Äì9, except that we train on G and test on T , and add new gold paragraphs
to G instead of T .

4

Data-Performance Tradeoffs in NER Models

As noted in Section 3.2, our model-in-the-loop annotation workflow requires repeated retraining of a SpaCy model. Thus we conducted experiments to understand how SpaCy prediction
performance is influenced by model size, quantity of training data, and amount of training
performed.
As the training data produced by the model-in-the-loop evaluation workflow are to be used
to train an NER model that we will apply to the entire CORD-19 dataset, we also evaluate the
Keras-LSTM model from the perspectives of big data accuracy and training time.

4.1

Model Size

F-1 score (%)

We first need to decide which SpaCy model to use for model-in-the-loop annotation. Model
size is a primary factor that affects training time and prediction performance. In general, larger
models tend to perform better, but require both more data and more time to train effectively. As
our model-in-the-loop annotation strategy requires frequent model retraining, and furthermore
will (initially at least) have little data, we hypothesize that a smaller model may be adequate
for our purposes.
To explore this hypothesis, we study the performance achieved by the SpaCy medium and
large models on our initial training set of 278 labeled paragraphs. We show in Figure 2 the
performance achieved by the two models as a function of number of training epochs. Focusing
on the harmonic mean of precision and recall, the F-1 score (a good measure a model‚Äôs ability
to recognize both true positives and true negatives), we see that the two models achieve similar
prediction performance, with the largest difference in F-1 score being around 2%. As the large
model takes over eight times longer to train per epoch, we select the medium model for modelin-the-loop data collection.

90
80
70
60
50
40
30
20
10
0

Md precision
Md recall
Md F-1
0

2

4

6

8

10

Lg precision
Lg recall
Lg F-1
12

Epoch

14

16

18

20

Figure 2: Precision, recall, and F-1 of medium and large SpaCy models trained on 278
examples.

6

F-1 score (%)

80
70
60
50
40
30
20
10
0

SpaCy
Keras
0

100 200 300 400 500 600 700 800 900 1000

Number of training examples

Figure 3: Training curve with different number of examples collected.

4.2

Amount of Training Data

As data labeling is expensive in both human time and model training time, it is valuable to
explore the tradeoff between time spent collecting data and prediction performance. To this
end, we manually labeled a set of 500 paragraphs selected at random from CORD-19 [3] as
a test set. Then, we used that test set to evaluate the results of training the SpaCy and
Keras-LSTM models of Section 3.1 on increasing numbers of the paragraphs produced by our
human-in-the-loop annotation process. Figure 3 shows their F-1 score curves as we scale from
0 to 1000 training samples. With only 100 training examples, SpaCy and Keras-LSTM achieve
F-1 scores of 57% and 66%, respectively. SpaCy performs better than Keras-LSTM with fewer
training examples (i.e., less than 300), after which Keras-LSTM overtakes it and maintains a
steady 2‚Äì3% advantage as the number of examples increases. This result motivates our choice
of Keras-LSTM for the CORD-19 studies in Section 6.
We stopped collecting training data after 1000 examples. We see in Figure 3 that the
performance of the SpaCy and Keras-LSTM models is essentially the same with 1000 training
examples as with 700 examples, with the F-1 score even declining when the number of available
examples increases to 800 or 900. At 1000 examples the F-1 score is greatest for both models.
We conclude that the 1000 training examples, along with the other 500 withheld as the test set,
are best-suited to train our models.

4.3

Training Epochs

Prediction performance is also influenced by the number of epochs spent in training. The cost
of training is particularly important in a model-in-the-loop setup, as human reviewers cannot
work while an model is offline for training.
Figure 4 shows the progression of the loss, precision, recall, and F-1 values of the SpaCy
model during 100 epochs of training with the initial 278 examples. We can see that the best
F-1 score is achieved within 10 to 20 epochs. Increasing the number of epochs does not result in
any further improvement. Indeed, F-1 score does not tell us all about the model‚Äôs performance.
Sometimes training for more epochs could lead to lower loss values while other metrics (such
as precision, recall, or F-1) no longer improve. That would still be desirable because it means
the model is now more ‚Äúconfident,‚Äù in a sense, about its predictions. However, that is not the
case here. As shown in Figure 4, after around 40 epochs the loss begins to oscillate instead of
continuing downwards, suggesting that in this case training for 100 epochs does not result in a
better model than only training for 20 epochs.
Figure 5 shows the progression of accuracy and loss value for the Keras-LSTM model with
the initial 278 examples. In Figure 5(a), we see that validation accuracy improves as training
accuracy increases during the first 50 epochs. After around epoch 50, the training and validation

7

80
70
60
50

Precision
Recall

40
30

0

10

20

30

40

50

Epoch

60

F-1
Loss
70

80

330
310
290
270
250
230
210
190
170
150

Loss (√ó103)

Precision, recall, F-1 (%)

90

90 100

1.00
0.99
0.98
0.97
0.96
0.95
0.94
0.93
0.92
0.91

5.7
5.5
5.3
Loss

CRF Accuracy

Figure 4: Loss, precision, recall, and F-1 of SpaCy model during training for 100 epochs on
278 paragraphs.

5.1
4.9
4.7

Train CRF Acc
Val CRF Acc
0

32

64

96

128 160
Epoch

192

224

4.5

256

(a) Accuracy

Train Loss
Val Loss
0

32

64

96

128 160
Epoch

192

224

256

(b) Loss

Figure 5: Training and validation accuracy and loss for Keras-LSTM model over 256 epochs.

accuracy curves diverge: the training accuracy continues to increase but the validation accuracy
plateaus. This trend is suggestive of overfitting, which is corroborated by Figure 5(b). After
about 50 epochs, the validation loss curve turns upwards. Hence we choose to limit the training
epochs to 64. After each epoch, if a lower validation loss is achieved, the current model state is
saved. After 64 epochs, we test the model with the lowest validation loss on the withheld test
set.

5

Evaluating Model and Human Performance

We conducted experiments to compare the performance of the SpaCy and Keras-LSTM NER
models; compare the performance of the models against humans; determine how training data
influences model performance; and analyze human and model errors.

5.1

Performance of SpaCy and Keras NER Models

We used the collected data of Section 3.2 to train both the SpaCy and Keras-LSTM NER models
of Section 3.1 to recognize and extract drug-like molecules in text. We find that the trained
en core web md SpaCy model achieved a best F-1 score of 77.3%, while the trained Keras-LSTM
model achieved a best F-1 score of 80.5%, somewhat outperforming SpaCy.
As shown in Figure 3, the SpaCy model performs better than the Keras-LSTM model when

8

trained with small amounts of training data‚Äîperhaps because of the different mechanisms
employed by the two methods to generate numerical representations for words. SpaCy‚Äôs built-in
language model, pre-trained on a general corpus of blog posts, news, comments, etc., gives it
some knowledge about commonly used words in English, which are likely also to appear in a
scientific corpus. On the other hand, the Keras-LSTM model uses custom word embeddings
trained solely on an input corpus, which provides it with better understanding of multi-sense
words, especially those that have quite different meanings in a scientific corpus. However,
without enough raw data to draw contextual information from, custom word embeddings can
not accurately reflect the meaning of words.

5.2

Comparison Against Human Performance

Recognizing drug-like molecules is a difficult task even for humans, especially non-medical professionals (such as our non-expert annotators). To assess the accuracy of the annotators, we
asked three people to examine 96 paragraphs, with their associated labels, selected at random
from the labeled examples. Two of these reviewers had been involved in creating the labeled
dataset; the third had not. For each paragraph, each reviewer decided independently whether
each drug molecule entity was labeled correctly (a true positive), was labeled as a drug when it
was not (a false positive), or was not labeled (a false negative). If all three reviewers agreed in
their opinions on a paragraph (the case for 88 of the 96 paragraphs), we accepted their opinions;
if they disagreed (the case for eight paragraphs), we engaged an expert.
This process revealed a total of 257 drug molecule entities in the 96 paragraphs, of which
the annotators labeled 201 correctly (true positives), labeled 49 incorrectly (false positives),
and missed 34 (false negatives). The numbers of true positives and false negatives do not sum
up to the total number of drug molecules because in some cases an annotator labeled not to
a drug entity but the entity plus extra preceding or succeeding word or punctuation mark
(e.g. ‚Äúsofosbuvir,‚Äù instead of ‚Äúsofosbuvir‚Äù) and we count such occurrences as false positives
rather than false negatives. In this evaluation, the non-expert annotators achieved an F-1 score
of 82.9%, which is comparable to the 80.5% achieved by our automated models, as shown in
Figure 3. In other words, our models have performance on par with that of non-expert humans.

5.3

Effects of Training Data Quality on Model Performance

We described in the previous section how review of 96 paragraphs labeled by the non-expert
annotators revealed an error rate of about 20%. This raises the question of whether model
performance could be improved with better training data. To examine this question, we compare
the performance of our models when trained on original vs. corrected data. As we only have 96
corrected paragraphs, we restrict our training sets to those 96 paragraphs in each case.
We sorted the 96 paragraphs in both datasets so that they are considered in the same order.
Then, we split each dataset into five subsets for K-fold cross validation (K =5), with the first
four subsets having 19 paragraphs each and the last subset having 20. Since K is set to five,
the SpaCy and Keras models are trained five times. In the i -th round, each model is trained
on four subsets (excluding the i -th) of each dataset. The i -th subset of the corrected dataset is
used as the test set. The i -th subset of the original dataset is not used in the i -th round.
We present the K-fold cross validation results in Tables 1 and 2. The models performed
reasonably well when trained on the original dataset, with an average F-1 score only 2% less
than that achieved with the corrected labels. Given that the expert input required for validation
is hard to come by, we believe that using non-expert reviewers is an acceptable tradeoff and
probably the only practical way to gather large amounts of training data.

5.4

Analysis of Human and Model Errors

Finally, we explore the contexts in which human reviewers and models make mistakes. Specifically, we study the tokens that appear most frequently near to incorrectly labeled entities. To

9

Table 1: K-fold (K=5) validation of the SpaCy model on 96 paragraphs with original vs.
corrected labels. The first five rows in each table are the results of each fold; the last row
is the average F-1 score of the five folds.
(b) Corrected labels

(a) Original labels

Precision
100.0
93.8
93.0
76.5
98.9
Average

Recall
25.6
50.6
63.5
45.2
92.3

F-1
40.7
65.7
75.5
57.1
95.5
66.9

Precision
100.0
88.9
92.0
68.6
99.2
Average

Recall
20.9
53.9
73.0
61.4
92.1

F-1
34.6
67.1
81.4
64.8
95.5
68.7

Table 2: K-Fold (K=5) validation of the Keras-LSTM model on 96 paragraphs with original
vs. corrected labels. The first five rows in each table are the results of each fold; the last
row is the average F-1 score of the five folds.
(b) Corrected labels

(a) Original labels

Precision
88.5
70.6
70.0
80.8
78.1
Average

Recall
53.5
57.8
67.7
55.3
56.8

F-1
66.7
63.6
68.9
65.6
65.8
66.1

Precision
80.6
90.2
82.9
80.8
75.0
Average

Recall
69.1
59.1
47.5
51.2
67.9

F-1
74.4
71.4
60.4
62.7
71.3
68.0

investigate the effects of immediate and long-distance context, we control, as window size, the
maximum distance between a token and a entity for that token to be considered as ‚Äúcontext‚Äù
for that entity.
One difficulty with this analysis is that the most frequent tokens identified in this way were
mostly stop words or punctuation marks. For instance, when the window size is set to three,
the 10 most frequent tokens around mislabeled words are, in descending order, ‚Äúcomma(,),‚Äù
‚Äúand,‚Äù ‚Äúmg,‚Äù ‚Äúperiod(.),‚Äù ‚Äúright parenthesis()),‚Äù ‚Äúwith,‚Äù ‚Äúof,‚Äù ‚Äúleft parenthesis((),‚Äù ‚Äúis,‚Äù and
‚Äúor.‚Äù Only ‚Äúmg‚Äù is neither a stop word nor punctuation mark.
Those tokens provide little insight as to why human reviewers might have made mistakes,
and furthermore are unlikely to have influenced reviewer decisions. Thus we exclude stopwords
and punctuation marks when providing, in Table 3, lists of the 10 most frequent tokens within
varying window sizes of words that were incorrectly identified as molecules by human reviewers.
We see that there are indeed several deceptive contextual words. With a window size of one,
the 10 most frequent tokens include ‚Äúoral,‚Äù ‚Äúdose,‚Äù and ‚Äúintravenous.‚Äù It is understandable
that an untrained reviewer might label as drugs words that immediately precede or follow such
context words. Similar patterns can be seen for window sizes of three and five. Without
background knowledge to draw from, non-experts are more likely to rely on their experience
gained from labeling previous paragraphs. One may hypothesize that after the reviewers have
seen a few dozen to a few hundred paragraphs, those deceptive contextual words must have
left a deep impression, so that when those words re-appear they are likely to label the strange
unknown word close to them as a drug.
To investigate this hypothesis, we also explored the most frequent words around drug entities
that are correctly labeled by human reviewers: see Table 4. Interestingly, we found overlaps
between the lists in Tables 3 and 4: in all, three, four, and two overlaps for window sizes of

10

Table 3: The 10 most frequent tokens, excluding stopwords and punctuation marks, within
various window sizes around entities incorrectly labeled by human reviewers.

#
1
2
3
4
5
6
7
8
9
10

window size = 1
Token
Count
300
4
oral
3
dose
3
intravenous
2
500
2
intravenously
1
include
1
Both
1
resistance
1
treatment
1

window size = 3
Token
Count
mg
19
once/day
7
treatment
6
300
5
treated
4
oral
4
once
4
dose
4
cidofovir
3
resistance
3

window size = 5
Token
Count
mg
23
daily
8
treatment
8
once/day
7
300
7
oral
6
recipients
5
treated
4
twice
4
include
4

one, three, and five, respectively, when treating all numerical values as identical. This finding
supports our hypothesis that those frequent words around real drug entities may confuse human
reviewers when they appear around non-drug entities.
Table 4: The 10 most frequent tokens, excluding stop words and punctuation marks, within
various window sizes around entities correctly labeled by human reviewers.

#
1
2
3
4
5
6
7
8
9
10

window size = 1
Token
Count
resistance
176
treatment
9
mM
4
oral
3
after
3
analogue
3
responses
3
antibiotics
2
exposure
2
pharmacokinetics
2

window size = 3
Token
Count
Tetracycline
230
resistance
177
Trimethoprim
118
treatment
11
20‚àº
7
Figure
5
concentration
5
compared
4
100
4
mM
4

window size = 5
Token
Count
Tetracycline
230
resistance
178
Trimethoprim
118
treatment
14
20‚àº
8
placebo
7
effects
6
Figure
6
KLK5
6
matriptase
6

We repeat this comparison of context words around human and model errors while considering stopwords and punctuation marks. Tables 5 and 6 show the 20 most frequent tokens in
each case. We see that 20‚Äì25% of the tokens in Table 5, but only 5‚Äì10% of those in Table 6,
are not stop words or punctuation marks. As the model only learns its word embeddings from
the input text, if a token often co-occurs with drug entities in the training corpus the model
will treat it as an indication of drug entities near its presence, regardless of whether or not it
is a stopword. This apparently leads the model to make incorrect inferences. Humans, on the
other hand, are unlikely to think that stopword such as ‚Äúthe‚Äù is indicative of drug entities, no
matter how frequently they appear together.

11

Table 5: The 20 most frequent tokens, including stop words and punctuation marks, within
various window sizes around entities incorrectly labeled by human reviewers. Words that
are neither stop words nor punctuation words are in boldface.

#
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

6

window size = 1
Token
Count
,
27
.
14
and
14
with
8
(
7
is
7
of
6
was
6
or
4
300
4
oral
3
has
3
to
3
[
3
dose
3
intravenous
2
in
2
may
2
500
2
a
2

window size = 3
Token
Count
,
49
and
21
mg
19
.
18
)
13
with
10
of
10
(
9
is
9
or
7
once/day
7
a
7
the
6
was
6
to
6
treatment
6
in
5
300
5
be
4
treated
4

window size = 5
Token
Count
,
74
.
28
and
28
mg
23
)
21
of
18
(
17
with
13
to
12
the
11
a
11
in
10
is
9
or
9
daily
8
was
8
treatment
8
]
8
once/day
8
were
7

Applying the Trained Models

After training the models with the labeled examples, we applied the trained models to the
entire CORD-19 corpus (2020-10-04 version with 198 875 articles) to identify potential drug-like
molecules. Processing a single article takes only a few seconds; we adapted our models to use
data parallelism to enable rapid processing of these many articles.
95

Full match
Partial match

90

90
Percent(%)

Percent(%)

80
70
60
50

Full match
Partial match

85
80
75
70

100 200 300 400 500 600 700 800 900 1000
Top candidates

(a) All Entities

65

100 200 300 400 500 600 700 800 900 1000
Top candidates

(b) Balanced Entities

Figure 6: Percentage of detected entities that are also found in DrugBank

12

Table 6: The 20 most frequent tokens, including stop words and punctuation marks, within
various window sizes around entities incorrectly labeled by the Keras model. Words that
are neither stop words nor punctuation words are in boldface.

#
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

window size = 1
Token
Count
,
166
(
86
and
81
of
58
)
30
to
28
or
24
.
22
mM
18
with
17
in
15
for
15
is
14
as
14
the
13
was
12
that
11
[
11
treatment
9
a
9

window size = 3
Token Count
,
347
and
126
(
117
)
89
of
85
the
73
to
60
.
48
with
44
a
41
in
37
or
35
was
33
mM
32
is
31
as
29
that
25
by
22
for
22
[
22

window size = 5
Token Count
,
468
and
176
(
162
)
143
of
130
the
121
to
85
in
75
with
72
.
68
a
62
was
52
or
47
is
43
for
42
that
37
mM
36
by
35
as
32
were
31

We ran the SpaCy model on two Intel Skylake 6148 processors with a total of 40 CPU cores;
this run took around 80 core-hours and extracted 38 472 entities. We ran the Keras model
on four NVidia Tesla V100 GPUs; this run took around 40 GPU-hours and extracted 121 680
entities. We recorded for each entity the number of the times that it has been recognized by
each model, and used those numbers as a voting mechanism to further determine which entities
are the most likely to be actual drugs. In our experiments, ‚Äúbalanced‚Äù entities (i.e., those
whose numbers of detection by the two models are within a factor of 10 of each other) are most
likely to appear in the DrugBank list. As shown in Figure 6, we sorted all extracted entities
in descending order by their total number of detection by both models, and when comparing
the the top 100 entities to DrugBank, only 77% were exact matches to drug names or aliases,
or 86% if we included partial matches (i.e., the extracted entity is a word within a multi-word
drug name or alias in DrugBank). In comparison, among the top 100 ‚Äúbalanced‚Äù entities, 88%
were exact matches to DrugBank, or 91% with partial matches.
Although DrugBank provides a reference metric to evaluate the results, it is not an exhaustive
ontology. For instance, remdesivir, a drug that has been proposed as a potential cure for COVID19, is not in DrugBank. We manually checked the top 50 ‚Äúbalanced‚Äù and top 50 ‚Äúimbalanced‚Äù
entities not matched to DrugBank, and found that 70% in the ‚Äúbalanced‚Äù list are actual drugs,
but only 26% in the ‚Äúimbalanced‚Äù list. Looking at the false positives in these top 50 lists,
the ‚Äúbalanced‚Äù false positives are often understandable. For example, in the sentence ‚ÄúELISA
plate was coated with . . . and then treated for 1h at 37.8C with dithiothreitol . . . ‚Äù, the model
mistook the redox reagent dithiothreitol for a drug entity, probably due to its context ‚Äútreated
with.‚Äù On the other hand, we found no such plausible explanations for the false positives in the

13

‚Äúimbalanced‚Äù list, where most false positives are chemical elements (e.g., silver, sodium), amino
acids (e.g., cysteine, glutamine), or proteins (e.g., lactoferrin, cystatin).
Finally, we compared our extraction results to the drugs being used in clinical trials, as listed
on the U.S. National Library of Medicine website ([15]). We queried the website with ‚Äúcovid‚Äù
as the keyword and manually screened the returned drugs in the ‚ÄúInterventions‚Äù column to
remove stopwords (e.g., tablet, injection, capsule) and dosage information (e.g., 2.5mg, 2.5%)
and only kept the drug names. Then we compared the top 50 most frequently appeared drugs
to the automatically extracted drugs from literature. The ‚Äúbalanced‚Äù entities extracted by both
models matched to 64% of the top 50 drugs in clinical trial, whereas the ‚Äúimbalanced‚Äù entities
only matched to 6% in the same list.
The results discussed here are available in the repository described in Section 7.

7

Data Availability and Formats

We have made our annotated training data, trained models, and the results of applying the
models to the CORD-19 corpus publicly available online. [16].
In order to facilitate training of various models, we published the training data in two
formats‚Äîan unsegmented version in line-delimited JSON (JSONL) format, and a segmented
version in Comma Separated Value (CSV) format. The JSONL format contains the most comprehensive information that we have collected on the paragraphs in the dataset. We choose
JSONL format rather than a JSON list because it allows for the retrieval of objects without
having to parse the entire file. A JSON object in the JSONL file has the following structure:
‚Ä¢ text: The original paragraph stored as a string without any modification.
‚Ä¢ tokens: The list of tokens from text after tokenization.
‚Äì
‚Äì
‚Äì
‚Äì

text: The text of the token as a string.
start: The index of the first character of the token in text.
end: The index of the first character after the token in text.
id: Zero-based numbering of the token.

‚Ä¢ spans: The list of spans (sequences of tokens) that are labeled as named entities (drugs)
‚Äì
‚Äì
‚Äì
‚Äì
‚Äì

start: The index of the first character of the span in text.
end: The index of the first character after the span in text.
token start: The index of the first token of the span in text.
token end: The index of the last token of the span in text.
label: The label of the span (‚Äúdrug‚Äù)

Another commonly adopted labeling scheme for NER datasets is the ‚ÄúIOB‚Äù labeling scheme,
in which the original text is first tokenized and each token is assigned a label ‚ÄúI,‚Äù ‚ÄúO,‚Äù or
‚ÄúB.‚Äù The label ‚ÄúB(eginning)‚Äù means the corresponding token is the first in a named entity. A
label ‚ÄúI(nside)‚Äù is given to every token in a named entity except for the first token. All other
tokens gets the label ‚ÄúO(utside)‚Äù which means they are not part of any named entity. The
aforementioned JSONL data are converted according to the IOB scheme and stored in Comma
Separated Value (CSV) files with one training example per line. Each line consists of two
columns: a first of tokens that made up of the original texts, and a second of the corresponding
IOB labels for those tokens. In addition to a different labeling scheme, the samples in the CSV
files are segmented, meaning that each sentence is treated as a training sample instead of an
entire paragraph. This structure aligns with that used in standard NER training sets such as
CoNLL03 [17].
The trained SpaCy and Keras models and the results of applying the models to the 198 875
articles in the CORD-19 corpus are also available in this GitHub repo. Additionally, the pretrained SpaCy model is provided as a cloud service via DLHub [13, 18]. (The Keras model
could not be hosted there due to compatibility issues with DLHub.) This cloud service allows
researchers to apply the model to any texts they provide with as few as four lines of code.

14

8

Conclusion and Future Directions

We have presented a human-machine hybrid pipeline for collecting training data for named
entity recognition models. We applied this pipeline to create an automated model for identifying
drug-like molecules in COVID-19-related research papers. Our pipeline facilitated efficient use
of valuable human resources by presenting human labellers only with samples that were most
likely to confuse our model. We explored various trade-offs, including model size, number of
training samples, and training epochs, to find the right balance between model performance
and time-to-result. In total, human reviewers working with our pipeline validated labels for 278
bootstrap samples, 1000 training samples, and 500 test samples. As this work was performed
in conjunction with other tasks, we cannot accurately quantify the total effort taken to collect
and annotate the above training and test samples, but it was likely around 100 person-hours.
NER models trained with these data achieved a best F-1 score of 80.5% when evaluated on
our collected test set. Our models have correctly identified 64% of the top 50 drugs that are
in clinical trials for COVID-19. The models were applied to 198 875 articles in the CORD-19
collection, from which we identified 10 912 molecules with potential therapeutic effects against
the SARS-CoV-2 coronavirus. The extracted molecule list were subsequently given to scientists
at Argonne National Laboratory to be used in computational screening pipelines. The code,
model, and extraction results are publicly available. In the future, we hope to further improve
NER model performance by integrating our models with more advanced language models.

Data and Code Availability
The datasets analyzed in this study can be found in the Kaggle dataset: https://www.kaggle.
com/allen-institute-for-ai/CORD-19-research-challenge.
The models used in this work and the datasets generated for this study can be found on GitHub
at https://github.com/globus-labs/covid-nlp/tree/master/drug-ner. The models are
also available on DLHub [18].

Acknowledgements
The data generated have been prepared as part of the nCov-Group Collaboration, a group
of over 200 researchers working to use computational techniques to address various challenges
associated with COVID-19.
This research was supported by the DOE Office of Science through the National Virtual
Biotechnology Laboratory, a consortium of DOE national laboratories focused on response to
COVID-19, with funding provided by the Coronavirus CARES Act. This research used resources
of the Argonne Leadership Computing Facility, a DOE Office of Science User Facility supported
under Contract DE-AC02-06CH11357. This work was also supported by financial assistance
award 70NANB19H005 from U.S. Department of Commerce, National Institute of Standards
and Technology as part of the Center for Hierarchical Materials Design (CHiMaD).
We are grateful to our human reviewers: India S. Gordon, Linda Novak, Kasia Salim, Susan
Sarvey, Julie Smagacz, and Monica Orozco White.

Disclaimer
Unless otherwise indicated, this information has been authored by an employee or employees
of the UChicago Argonne, LLC, operator of the Argonne National laboratory with the U.S.
Department of Energy. The U.S. Government has rights to use, reproduce, and distribute this
information. The public may copy and use this information without charge, provided that this
Notice and any statement of authorship are reproduced on all copies.

15

While every effort has been made to produce valid data, by using this data, User acknowledges that neither the Government nor UChicago Argonne LLC makes any warranty, express or
implied, of either the accuracy or completeness of this information or assumes any liability or
responsibility for the use of this information. Additionally, this information is provided solely
for research purposes and is not provided for purposes of offering medical advice. Accordingly,
the U.S. Government and UChicago Argonne LLC are not to be liable to any user for any loss
or damage, whether in contract, tort (including negligence), breach of statutory duty, or otherwise, even if foreseeable, arising under or in connection with use of or reliance on the content
displayed on this site.

References
1.

Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track
COVID-19 in real time. The Lancet infectious diseases 20, 533‚Äì534 (2020).

2.

Allen Institute For AI. COVID-19 Open Research Dataset Challenge https://
www.kaggle.com/allen- institute- for- ai/CORD- 19- research- challenge.
2020.

3.

Wang, L. L. et al. CORD-19: The COVID-19 Open Research Dataset Preprint
2004.10706 (ArXiv, 2020).

4.

Tchoua, R. et al. Active learning yields better training data for scientific named
entity recognition in 15th International Conference on eScience (2019), 126‚Äì135.

5.

Tchoua, R. B. et al. Creating training data for scientific named entity recognition
with minimal human effort in International Conference on Computational Science
(2019), 398‚Äì411.

6.

Hong, Z., Tchoua, R., Chard, K. & Foster, I. SciNER: Extracting Named Entities
from Scientific Literature in International Conference on Computational Science
(2020), 308‚Äì321.

7.

Bullard-Feibelman, K. M. et al. The FDA-approved drug Sofosbuvir inhibits Zika
virus infection. Antiviral Research 137, 134‚Äì140 (2017).

8.

Wishart, D. S. et al. DrugBank 5.0: A major update to the DrugBank database
for 2018. Nucleic Acids Research 46, D1074‚ÄìD1082 (2018).

9.

Center for Drug Evaluation and Research. About Drugs@FDA https://www.fda.
gov/drugs/drug-approvals-and-databases/about-drugsfda. 2020.

10.

Nadeau, D. & Sekine, S. A survey of named entity recognition and classification.
Lingvisticae Investigationes 30, 3‚Äì26 (2007).

11.

Oestereich, L. et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T705 (Favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS
Neglected Tropical Diseases 8, e2804 (2014).

12.

Chiu, J. P. & Nichols, E. Named entity recognition with bidirectional LSTM-CNNs.
Transactions of the Association for Computational Linguistics 4, 357‚Äì370 (2016).

13.

Li, Z. et al. DLHub: Simplifying publication, discovery, and use of machine learning models in science. Journal of Parallel and Distributed Computing 147, 64‚Äì76
(2021).

14.

Weischedel, R. et al. OntoNotes release 5.0. Linguistic Data Consortium, Philadelphia, PA 23 (2013).
16

15.

National Institutes of Health. U.S. COVID-19 Clinical Trials https://clinicaltrials.
gov/ct2/results?cond=covid&cntry=US. 2020.

16.

Babuji, Y. et al. Lit - A Collection of Literature Extracted Small Molecules to
Speed Identification of COVID-19 Therapeutics Materials Data Facility. https:
//github.com/globus-labs/covid-nlp/tree/master/drug-ner. 2020.

17.

Sang, E. F. & De Meulder, F. Introduction to the CoNLL-2003 shared task: Languageindependent named entity recognition in 7th Conference on Natural Language Learning (2003), 142‚Äì147.

18.

Hong, Z. et al. A Model to Extract Drug-like Molecules from Natural Language
Text. Data and Learning Hub for Science. 2020.

17

